AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Dr. Reddy's Laboratories ... (RDY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

13.56

-0.04 (-0.29%)

At close: Feb 18, 2025, 3:59 PM

13.56

-0.04%

After-hours: Feb 18, 2025, 07:00 PM EST

undefined% (undefined)

Bid	13.49
Market Cap	11.30B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.74
PE Ratio (ttm)	18.33
Forward PE	n/a
Analyst	Buy

Ask	13.71
Volume	2,248,882
Avg. Volume (20D)	1,756,861
Open	13.63
Previous Close	13.60
Day's Range	13.48 - 13.65
52-Week Range	13.36 - 16.89
Beta	undefined

About RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finish...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Apr 11, 2001

Employees 27,048

Stock Exchange NYSE

Ticker Symbol RDY

Website https://www.drreddys.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 25.32% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Dr. Reddy's Laboratories Limited is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

-6.23%

Dr. Reddy's Laboratories shares are trading lower.... Unlock content with Pro Subscription

7 months ago

+4.65%

Dr. Reddy's Laboratories shares are trading higher. The company on Wednesday announced it signed a definitive agreement with Haleon for purchase of shares of Northstar Switzerland SARL to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category outside of the United States.

News

1 week ago · businesswire.com

Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.

2 weeks ago · seekingalpha.com

Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns

Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the a...

3 weeks ago · zacks.com

RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

3 weeks ago · seekingalpha.com

Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q3 2025 Earnings Conference Call January 23, 2025 9:00 AM ET Company Participants Richa Periwal – Head-Investor Relations and Analytics Erez Israeli – Chie...

3 weeks ago · businesswire.com

Dr. Reddy's Q3 & 9MFY25 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #9MFY25--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.

2 months ago · zacks.com

3 Emerging Market Stocks to Buy as 2024 Wraps Up

Here, we have picked three emerging market stocks, QFIN, YTRA and RDY, which are expected to show robust growth in 2025 on their growth strategies and fundamentals.

2 months ago · zacks.com

Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio

RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.

2 months ago · zacks.com

RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma

Dr. Reddy's launches Loqtorzi biosimilar in India under the brand name Zytorvi for treating adults with recurrent or metastatic nasopharyngeal carcinoma.

2 months ago · businesswire.com

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India.

2 months ago · businesswire.com

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DrReddys--Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg in the U.S. market.